NATERA, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NATERA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $933.00K, a 174.41% increase year-over-year.
- NATERA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $3.86M, a 610.11% increase year-over-year.
- NATERA, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $19.72M, a 652.56% increase year-over-year.
- NATERA, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.94M, a 12.50% increase year-over-year.
- NATERA, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $22.54M, a 73.51% increase from fiscal 2024.
- NATERA, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $12.99M, a 233.71% increase from fiscal 2023.
- NATERA, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $3.89M, a 39.29% decline from fiscal 2022.
- NATERA, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $6.41M, a 45.74% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $933.00K 10-Q · filed 2026-08-07 | $26.45M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $3.86M 10-Q · filed 2026-05-08 | $25.86M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $19.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $22.54M 10-K · filed 2026-02-27 |
| 2025-09-30 | $1.94M 10-Q · filed 2025-11-07 | $5.44M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $340.00K 10-Q · filed 2026-08-07 | $5.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $544.00K 10-Q · filed 2026-05-08 | $7.07M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.99M 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.72M 10-Q · filed 2025-11-07 | $10.76M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $2.18M 10-Q · filed 2025-08-08 | $9.60M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $6.47M 10-Q · filed 2025-05-09 | $8.06M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.89M 10-K · filed 2026-02-27 |
| 2023-09-30 | $562.00K 10-Q · filed 2024-11-12 | $3.94M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $638.00K 10-Q · filed 2024-08-09 | $4.77M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.30M 10-Q · filed 2024-05-10 | $4.56M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $6.41M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.39M 10-Q · filed 2023-11-09 | $7.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $422.00K 10-Q · filed 2023-08-04 | $9.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $4.16M 10-Q · filed 2023-05-10 | $11.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $11.82M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.94M 10-Q · filed 2022-11-09 | $18.52M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $2.26M 10-Q · filed 2022-08-05 | $19.55M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $4.57M 10-Q · filed 2022-05-06 | $24.27M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $23.52M 10-K · filed 2023-03-01 |
| 2020-09-30 | $4.97M 10-Q · filed 2021-11-05 | $18.41M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $6.98M 10-Q · filed 2021-08-06 | $17.86M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $3.83M 10-Q · filed 2021-05-07 | $14.29M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $13.04M 10-K · filed 2022-02-25 |
| 2019-09-30 | $4.43M 10-Q · filed 2020-11-06 | $11.68M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $3.40M 10-Q · filed 2020-08-07 | $15.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $2.58M 10-Q · filed 2020-05-08 | $15.35M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $13.33M 10-K · filed 2021-02-26 |
| 2018-09-30 | $7.87M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $3.63M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $564.00K 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $2.31M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $3.60M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $1.26M 10-K · filed 2018-03-15 | |
| 2014-12-31 | $169.00K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $259.00K 10-K · filed 2016-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |